Sabestomig - Astrazeneca
Alternative Names: AZD-7789Latest Information Update: 26 Apr 2024
At a glance
- Originator AstraZeneca
- Class Antineoplastics; Bispecific antibodies; Immunotherapies
- Mechanism of Action Antibody-dependent cell cytotoxicity; HAVCR2 protein inhibitors; Programmed cell death 1 receptor antagonists; T lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Adenocarcinoma
- Phase I/II Hodgkin's disease; Solid tumours
Most Recent Events
- 16 Apr 2024 Presage Biosciences and AstraZeneca plans a phase 0 trial for Squamous cell carcinoma (Metastatic disease, Recurrent) in USA (Intratumoural, Injection) in April 2024 (NCT06366451)
- 09 Dec 2023 Efficacy and adverse events data from a phase I/II trial in Hodgkin's disease presented at the 65th American Society of Hematology Annual Meeting and Exposition (ASH-Hem-2023)
- 30 Nov 2023 AstraZeneca in-licenses CIVO® technology from Presage Biosciences